Programme 19 : Thoracic Cancers

Programme 19 : Thoracic Cancers

PROGRAM LEADERS

Pr Pierre MORDANT, is a thoracic and vascular surgeon with an additional competency in surgical oncology. After an initial training in Paris and Toronto, Pierre has been a consultant surgeon at Bichat Hospital since 2014 and a full professor at Université Paris Cité since 2018. His main topic of interests included robotic-assisted thoracic surgery for localized tumors, multimodal management for locally advanced non-small cell lung cancer, and enhanced recovery after surgery for all patients.

HEALTHCARE EXECUTIVE

Sandrine GERARD

Dr Valérie GOUNANT, M.D. M.Sc., was initially trained at Nancy Medical School, then at Sorbonne University (Paris 6). She is the deputy Head of the Bichat Hospital thoracic oncology department. She was a pioneer in developing EndoBronchial Ultra-Sound (EBUS) systematic mediastinal nodes sampling for lung cancer staging. She developed expertise in thoracic oncology clinical research, as an active member of CIC INSERM 1425/CLIP2 Unit, dedicated to early phases clinical trials in lung cancer. She recently developed simulation teaching of clinical trial presentation to patients, studying the impact of such simulation formation in young investigators, to relieve their anxiety and increase their accrual abilities in clinical trials.

Key Number P19 cancer thoracique

STRENGTHS IN THE FOLLOWING AREAS

Cancer Care

The thoracic oncology activities of the Institute of Cancer AP-HP.Nord Université Paris Cité is articulated around a dedicated department at Bichat hospital, including a dedicated clinical research unit for early phase clinical trials (CIC INSERM 1425), a thoracic surgery department at Bichat hospital, and 2 departments, respectively at Saint-Louis Hospital (Medical Oncology Department) and Louis-Mourier Hospital (Pulmonology Department), also following and treating patients with thoracic cancer according to common procedures and protocols with Bichat’s teams.

It has 79 places dedicated to thoracic oncology, all facilities to optimally manage primary and advanced tumors including rare tumors (European expertise on mesothelioma, thymoma) using innovative approaches (video assisted surgery, robotic assisted surgery, interventional radiology and new therapeutic agents within clinical trials).

Research

The group is affiliated to 5 research INSERM units and produces high level basic and translational research with 33 publications in top level journals (A rank) including Lancet, Lancet Oncol, Cancer Discov., Nature Med., Sience, JAMA oncol., JCO, JTO.

  • FHU, SIRIC, RHU:

FHU APPOLLO, MOSAIC, TORINO lumiere

  • Basic science:

U1152 INSERM
U830 INSERM
CIC INSERM 1425
UMR 1149 INSERM
U1162 INSERM FunGEST

Education

Besides teaching lung cancer topic for medical internship university program (Medicine Faculty of Université Paris Cité), the thoracic oncologists are involved in national courses organized by the French Society of Pulmonology (SPLF), and specifically were in charge of the organization of the annual national course of thoracic oncology entitled « Cours du GOLF » from the Group of Oncology in French Langage, in Paris (2019) and Caen (2022). They also participate each year to national course of CRAs in Oncology (ARTEC) organized by the French Cooperative Oncology Groups (GCO), and the national course for clinical research investigators (INVEST) organized by the French Intergroup of Thoracic cancers (IFCT). Prof. G. Zalcman, as Faculty member of ESMO, ASCO, IASLC and ERS has given a dozen of talks at ASCO, ESMO, ELCC, ERS and IASCLC international meetings during the last 15 years, while being invited to give seminars by the Institut Jules Bordet (Brussels), by the NIH joint committee on Cancer and COVID, the French Speaking Belgium Pulmonology Association, the national league against cancer, the IUCT Oncopole of Toulouse.

Dr. Gounant and Prof. Pierre Mordant have been invited to give talks and presentations at national meetings on various topics including echo-endoscopy, robotic surgery, improve post-surgery rehabilitation, targeted therapy, immunotherapy, etc.